NEW YORK, Nov. 19 /PRNewswire-Asia-FirstCall/ -- Zacks Equity Research has
initiated investment research coverage on Sinobiopharma, Inc. (OTC Bulletin
Board: SNBP) with an Outperform and six month target price of $0.80. Jiangsu,
China-based SNBP, known domestically as Dong Ying Pharmaceutical Co. Ltd., is
a fully integrated and high growth company engaged in the R&D, manufacture and
distribution of biopharmaceutical products. The company focuses primarily on
the development of anesthesia-assisted agents as well as antibiotics for
penicillin-allergic patients and cardiovascular-related products related to
high blood pressure (commercial in October 2009). KuTai, SNBP's flagship
product is a first-to-market Cisatracurium Besylate injectable that serves as
a low cost skeletal muscle relaxant used during pre-surgical and surgical
procedures. The company holds five patents in Chiral Pharmaceutical
Ingredient Synthesis and Purification, and Molecular Packaging Formulation
(see proprietary technology section) and has the longer-term ability to expand
both the breadth of its product line and market share through R&D partnerships
with Cornell University, Nanjing University, China Pharmaceutical University,
and Nanjing Medical University.
About Zacks Equity Research
Founded in 1978 in Chicago, Zacks Investment Research, Inc. is one of the
largest independent investment research and consulting firms in the United
States. With 30 years of experience, dedicated to providing clients with the
highest standards of services, Zacks has become an industry leader in
providing institutional and individual investors with the analytical tools and
financial information necessary to the success of their investment process.
Zacks provides clients with professional services in the area of
investment research, wealth management, and investment consulting. This
information is made available through institutional and non-institutional
product lines and web sites, as well as Zacks' own websites
http://www.zacks.com , http://www.zacksadvisor.com , and
http://www.zackspro.com .
SOURCE Sinobiopharma, Inc.